ALMS
ALUMIS INC.
NASDAQ · Healthcare · Biotechnology · US
$5.85
−10.69%Price chart
Oct 7Oct 12Oct 15Oct 20Oct 23Oct 28Nov 2Nov 5
Key dataNov 5, 2026
Open$6.50
From 52W high−80.69%
Volume1.95M
Market cap$757.20M
P/E (TTM)—
P/S (TTM)102.4x
Div yield—
Key dataNov 5, 2026
Open
$6.50
From 52W high
−80.69%
Volume
1.95M
Market cap
$757.20M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.7x
P/E (TTM)
—
RSI (14)
32.4
MomentumView details →
1D Return
−10.69%
YTD Return
−38.01%
SummaryUpdated Jun 1, 2026
Alumis Inc. (NASDAQ:ALMS) is a clinical-stage biopharmaceutical company founded in 2021 and headquartered in South San Francisco, California. Originally incorporated as Esker Therapeutics, Inc., the company rebranded to Alumis Inc. in January 2022 before going public in February 2021. The company focuses on developing innovative medicines for autoimmune and inflammatory disorders, with its lead programs targeting a specific enzyme pathway called tyrosine kinase 2 (TYK2) that plays a crucial role in immune system regulation.
Similar companies
Latest newsMore news →
Alumis announced new Phase 3 clinical data for envudeucitinib from the ONWARD1, ONWARD2 and ONWARD3 programs, reporting improvements in psoriasis burden across scalp, itch and quality-of-life measures.28d agoALUMIS stock resumed trading and plunged 57% in premarket after a failed trial sale.66d agoAlumis announced topline results from its ONWARD3 long-term extension study, showing envudeucitinib achieved high skin clearance rates in psoriasis patients.88d ago